erlotinib hydrochloride has been researched along with Adverse Drug Event in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (11.54) | 29.6817 |
| 2010's | 20 (76.92) | 24.3611 |
| 2020's | 3 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| George, C; Joshua, JM; Pavithran, K; Thomas, P; Vijayan, M; Vincent, B | 1 |
| DerSarkissian, M; Duh, MS; Fernandes, AW; Laliberté, F; Pavilack, M; Subramanian, J | 1 |
| Chen, H; Huang, J; Luo, Z; Meng, L; Sun, S; Yang, B | 1 |
| Chen, KH; Tseng, LC; Wang, CL; Weng, LC | 1 |
| Dame, K; Grafton, F; Loewke, K; Maddah, M; Mandegar, MA; Ribeiro, AJS | 1 |
| Bury, MJ; Gandara, DR; Hirsch, FR; Kelly, K; Kwong, M; Mack, P; Miao, J; Moon, J; Moore, DF; Nguyen, DD; Redman, M; West, HL; Wozniak, AJ | 1 |
| Goto, K; Kato, T; Khaznadar, T; Nishio, M; Okamoto, I; Seki, A; Seto, T; Shibata, M; Tajima, K; Tao, L; Yamamoto, N; Yu, W | 1 |
| Endo-Tsukude, C; Fujii, S; Hamada, A; Hayashi, M; Inaba, M; Isobe, T; Iwamoto, N; Kai, Y; Kashiwabara, K; Kishi, H; Kohrogi, H; Saeki, S; Saito, H; Sasaki, JI; Semba, H; Tsubata, Y; Ushijima, S | 1 |
| Chen, Y; Gu, Y; Jiang, X; Liu, Y | 1 |
| Alesini, D; Bria, E; Cantile, F; Ciardiello, F; Cortesi, E; Fasano, M; Morgillo, F; Passaro, A; Pellegrino, A | 1 |
| Adamo, V; David, A; Franchina, T; Gangemi, S; Kennez, I; Minciullo, PL; Profita, M; Zanghì, M | 1 |
| Berlin, J; Cardin, DB; Chan, E; DeVore, R; Goff, L; Grigorieva, J; Holloway, M; Li, CI; McClanahan, P; Meyer, K; Schlabach, L; Shyr, Y; Winkler, C | 1 |
| Al-Kali, A; Cherry, M; Ghabache, B; Khawandanah, M; Ozer, H; Selby, G; Srour, S; Zhao, ZJ | 1 |
| Amler, LC; Baselga, J; Blumenschein, GR; Bohórquez, SS; Calles, A; Cervantes, A; Dienstmann, R; Hidalgo, M; Jimeno, A; Juric, D; Kapp, AV; Leddy, C; Littman, C; Messersmith, W; Penuel, E; Pirzkall, A; Roda, D; Shames, DS; Tabernero, J; Wang, X | 1 |
| Guo, J; Han, X; Hu, GF; Liu, LY; Tang, N; Wang, X; Wang, Y; Wang, ZH; Zhang, QQ | 1 |
| Chang, JC; Iqbal, A; Jakubowski, CD; Paik, PK; Plodkowski, AJ; Rekhtman, N; Yu, HA | 1 |
| Heinonen, T; Huttala, O; Mannerström, M; Sabell, E; Sarkanen, JR; Toimela, T; Ylikomi, T | 1 |
| Saif, MW | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Gray, J; Haura, EB; Litschauer, S; Neuger, A; Rawal, B; Schell, MJ; Simon, G; Song, L; Tanvetyanon, T; Tetteh, L; Williams, C | 1 |
| Franklin, G; Kalaichelvan, VK; Manavalan, R; Marslin, G; Reddy, PN; Sheeba, CJ | 1 |
| Backes, WH; Brans, B; de Langen, AJ; Dingemans, AC; Groen, HJM; Hoekstra, OS; Marcus, JT; Pruim, J; Scholtens, HTGM; Smit, EF; Thunnissen, FB; van den Boogaart, V; van Tinteren, H | 1 |
| Heigener, D; Mok, T; Reck, M; Wolf, J; Wu, YL | 1 |
| Carlson, JJ; Reyes, C; Veenstra, DL; Wong, WB | 1 |
| Boshoff, C; Bulley, S; Chao, D; Falk, S; Hackshaw, A; Hatton, M; Jones, R; Khan, I; Lal, R; Lee, SM; Lewanski, C; Marshall, E; Middleton, G; Ngai, Y; Rudd, R; Skailes, G; Toy, E; Upadhyay, S; Woll, PJ | 1 |
| Chen, GY; Cheng, Y; Huang, C; Huang, YS; Liu, Y; Lu, S; Ren, S; Wu, YL; Yan, HH; Yang, JJ; Zhou, C | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
3 review(s) available for erlotinib hydrochloride and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2016 |
Reviewing the safety of erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Product Surveillance, Postmarketing; Quinazolines | 2011 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
9 trial(s) available for erlotinib hydrochloride and Adverse Drug Event
| Article | Year |
|---|---|
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cigarette Smoking; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2018 |
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2018 |
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Quinazolines; Sorafenib | 2014 |
Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera.
Topics: Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Humans; Janus Kinase 2; Male; Middle Aged; Phenylalanine; Polycythemia Vera; Quinazolines; Treatment Outcome; Valine | 2015 |
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Immunoglobulin G; Male; Middle Aged; Panitumumab; Receptor, ErbB-3; Squamous Cell Carcinoma of Head and Neck | 2015 |
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Dasatinib; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Vascular Endothelial Growth Factor A | 2010 |
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tomography, Emission-Computed; Treatment Outcome | 2011 |
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Quinazolines | 2013 |
14 other study(ies) available for erlotinib hydrochloride and Adverse Drug Event
| Article | Year |
|---|---|
A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Smoking | 2019 |
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Health Resources; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; United States | 2019 |
Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
Topics: Acrylamides; Adverse Drug Reaction Reporting Systems; Afatinib; Aniline Compounds; Data Mining; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Pharmacovigilance; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Safety; United States; United States Food and Drug Administration | 2020 |
Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study.
Topics: Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Correlation of Data; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Skin; Surveys and Questionnaires; Taiwan | 2020 |
Quantifying drug-induced structural toxicity in hepatocytes and cardiomyocytes derived from hiPSCs using a deep learning method.
Topics: Antineoplastic Agents; Biological Assay; Cardiotoxicity; Cells, Cultured; Deep Learning; Doxorubicin; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Hepatocytes; Humans; Induced Pluripotent Stem Cells; Myocytes, Cardiac; Sorafenib; Tamoxifen; Toxicity Tests | 2020 |
Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
Topics: Aged; Antineoplastic Agents; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Glucuronosyltransferase; Humans; Lung Neoplasms; Male; Models, Biological; Polymorphism, Single Nucleotide; Prospective Studies | 2018 |
Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor.
Topics: Allyl Compounds; Animals; Antineoplastic Agents; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasms; Protein Kinase Inhibitors; Skin; Sulfides | 2019 |
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?
Topics: Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity.
Topics: Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Interleukin-33; Interleukins; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin | 2013 |
Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Remission Induction; Tomography, X-Ray Computed; Withholding Treatment | 2017 |
Intra-laboratory validated human cell-based in vitro vasculogenesis/angiogenesis test with serum-free medium.
Topics: 2-Methoxyestradiol; Adipose Tissue; Aspirin; Cells, Cultured; Culture Media; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Estradiol; Human Umbilical Vein Endothelial Cells; Humans; Laboratories; Levamisole; Mannitol; Methimazole; Neovascularization, Physiologic; Reproducibility of Results; Serum; Stromal Cells; Teratogens; Toxicity Tests; Umbilical Cord; Vascular Endothelial Growth Factor A | 2017 |
Hepatic failure and hepatorenal syndrome secondary to erlotinib. Safety reminder.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Hepatorenal Syndrome; Humans; Liver Failure; Product Surveillance, Postmarketing; Protein Kinase Inhibitors; Quinazolines | 2008 |
Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces Erlotinib-induced subacute toxicity in rat.
Topics: Animals; Dose-Response Relationship, Drug; Drug Compounding; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Lactic Acid; Materials Testing; Nanocapsules; Nanomedicine; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinazolines; Rats; Rats, Wistar | 2009 |
Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Budgets; Carcinoma, Non-Small-Cell Lung; Centers for Medicare and Medicaid Services, U.S.; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Models, Economic; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Registries; Taxoids; United States | 2011 |